Molecular weight (DA)
125(200kd BCR-ABL complex）
Immunogen
The antiserum was produced against synthesized peptide derived from human Abl around the phosphorylation site of Tyr412. AA range:361-410
Specificity
Phospho-Abl1/2 (Y393/439) Polyclonal Antibody detects endogenous levels of Abl1/2 protein only when phosphorylated at Y393/439.
Formulation
Liquid in PBS containing 50% glycerol, 0.5% BSA and 0.02% sodium azide.
Dilution rate
WB: 1/500 - 1/2000. IHC: 1/100 - 1/300. ELISA: 1/10000.. IF 1:50-200
Purification process (Immunogen)
The antibody was affinity-purified from rabbit antiserum by affinity-chromatography using epitope-specific immunogen.
Background
This gene is a protooncogene that encodes a protein tyrosine kinase involved in a variety of cellular processes, including cell division, adhesion, differentiation, and response to stress. The activity of the protein is negatively regulated by its SH3 domain, whereby deletion of the region encoding this domain results in an oncogene. The ubiquitously expressed protein has DNA-binding activity that is regulated by CDC2-mediated phosphorylation, suggesting a cell cycle function. This gene has been found fused to a variety of translocation partner genes in various leukemias, most notably the t(9;22) translocation that results in a fusion with the 5' end of the breakpoint cluster region gene (BCR; MIM:151410). Alternative splicing of this gene results in two transcript variants, which contain alternative first exons that are spliced to the remaining common exons. [pr
Function
catalytic activity:ATP + a [protein]-L-tyrosine = ADP + a [protein]-L-tyrosine phosphate.,cofactor:Magnesium or manganese.,disease:A chromosomal aberration involving ABL1 is a cause of chronic myeloid leukemia (CML) [MIM:608232]. Translocation t(9;22)(q34;q11) with BCR. The translocation produces a BCR-ABL found also in acute myeloid leukemia (AML) and acute lymphoblastic leukemia (ALL).,enzyme regulation:Stabilized in the inactive form by an association between the SH3 domain and the SH2-TK linker region, interactions of the amino-terminal cap, and contributions from an amino-terminal myristoyl group and phospholipids. Activated by autophosphorylation as well as by SRC-family kinase-mediated phosphorylation. Activated by RIN1 binding to the SH2 and SH3 domains. Inhibited by imatinib mesylate (Gleevec) which is used for the treatment of chronic myeloid leukemia (CML).,function:Regulates
Protein name
Tyrosine-protein kinase ABL1/2
Other name
ABL1; ABL; JTK7; Tyrosine-protein kinase ABL1; Abelson murine leukemia viral oncogene homolog 1; Abelson tyrosine-protein kinase 1; Proto-oncogene c-Abl; p150; ABL2; ABLL; ARG; Abelson tyrosine-protein kinase 2; Abelson murine leukemia vira
Fields
>>ErbB signaling pathway;>>Ras signaling pathway;>>Cell cycle;>>Axon guidance;>>Neurotrophin signaling pathway;>>Pathogenic Escherichia coli infection;>>Pathways in cancer;>>MicroRNAs in cancer;>>Chemical carcinogenesis - reactive oxygen species;>>Chronic myeloid leukemia;>>Viral myocarditis
Human protein sequence Database
P00519/P42684
Mouse protein sequence database
Rat protein sequence database
Cellular localization
Cytoplasm, cytoskeleton. Nucleus. Mitochondrion . Shuttles between the nucleus and cytoplasm depending on environmental signals. Sequestered into the cytoplasm through interaction with 14-3-3 proteins. Localizes to mitochondria in response to oxidative stress (By similarity). .; [Isoform IB]: Nucleus membrane; Lipid-anchor. The myristoylated c-ABL protein is reported to be nuclear.
Tissue expression
Widely expressed.
Contract Us
Follow Us
Location： 
Specification
成功添加到购物车